A 45-year-old male with community-acquired pneumonia develops acute respiratory distress over 3 days. Chest X-ray shows bilateral diffuse opacities. Arterial blood gas on FiO2 0.6 and PEEP 8 cm H2O shows PaO2 85 mmHg. Lung biopsy (performed for diagnostic confirmation) reveals the structure marked **C** in the diagram — pink eosinophilic linings lining the distal alveolar walls composed of fibrin, plasma proteins, and necrotic cellular debris. Which of the following management strategies has demonstrated mortality benefit in this clinical scenario according to landmark trials?

Explanation

## Why Lung-protective ventilation with tidal volume 6 mL/kg ideal body weight and plateau pressure < 30 cm H2O is right The presence of hyaline membranes (structure **C**) is the histopathologic hallmark of diffuse alveolar damage (DAD), which defines ARDS. The ARDSNet trial (2000) demonstrated that lung-protective ventilation using low tidal volumes (6 mL/kg ideal body weight) with plateau pressure limitation (<30 cm H2O) reduced mortality by approximately 22% compared to conventional ventilation (10-12 mL/kg). This is the cornerstone of ARDS management and is supported by both Robbins 10e and Harrison 21e as the evidence-based standard of care (Robbins 10e Ch 15; Harrison 21e Ch 294). ## Why each distractor is wrong - **High-dose methylprednisolone (1 g IV daily for 7 days)**: Steroids in ARDS remain controversial and have NOT shown mortality benefit in the general ARDS population. Steroids are only recommended in specific contexts such as COVID-ARDS (RECOVERY trial showed dexamethasone benefit) or ARDS secondary to autoimmune causes. Routine high-dose steroid use is not standard practice. - **Immediate intubation with conventional tidal volume 10-12 mL/kg to maximize oxygenation**: This represents the older, discredited approach to ARDS ventilation. The ARDSNet trial explicitly demonstrated that conventional high tidal volumes increase barotrauma and worsen outcomes. This strategy is contraindicated in ARDS. - **Routine use of inhaled nitric oxide for all ARDS patients**: While inhaled nitric oxide (iNO) may transiently improve oxygenation in some ARDS patients, multiple trials (including NHLBI ARDS Network trials) have shown NO mortality benefit with routine iNO use. It is not recommended as standard therapy for all ARDS patients. **High-Yield:** Hyaline membranes = DAD = ARDS; lung-protective ventilation (6 mL/kg IBW, Pplat <30) is the only proven mortality-reducing intervention in ARDS (ARDSNet trial). [cite: Robbins 10e Ch 15; Harrison 21e Ch 294]